Journal
CELLS
Volume 9, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cells9122691
Keywords
Siglec; sialic acid; glycan; antibody; CAR
Categories
Funding
- European Research Council [788143-RECGLYC-ANMR]
- Marie-Sklodowska-Curie actions (TN BactiVax) [860325]
- Agencia Estatal de Investigacion (Spain) [PID2019-107770RA-I00]
- Severo Ochoa Excellence Accreditation [SEV-2016-0644]
- Marie Curie Actions (MSCA) [860325] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
The sialic acid-binding immunoglobulin-type of lectins (Siglecs) are receptors that recognize sialic acid-containing glycans. In the majority of the cases, Siglecs are expressed on immune cells and play a critical role in regulating immune cell signaling. Over the years, it has been shown that the sialic acid-Siglec axis participates in immunological homeostasis, and that any imbalance can trigger different pathologies, such as autoimmune diseases or cancer. For all this, different therapeutics have been developed that bind to Siglecs, either based on antibodies or being smaller molecules. In this review, we briefly introduce the Siglec family and we compile a description of glycan-based molecules and antibody-based therapies (including CAR-T and bispecific antibodies) that have been designed to therapeutically targeting Siglecs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available